New discoveries still abundant in monoclonal antibody research.
Garber
K
K
D000617:Aminoglycosides; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017209:Apoptosis; D001402:B-Lymphocytes / Q000276:immunology; D000068818:Cetuximab; D017024:Chemotherapy, Adjuvant; D017326:Clinical Trials, Phase III as Topic; D004345:Drug Industry; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D018714:Radiotherapy, Adjuvant; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011993:Recombinant Fusion Proteins; C417039:Y2B8 monoclonal antibody; C119496:tositumomab I-131; D000068818:Cetuximab